Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors

Human Gene Therapy

Volumn 8, Issue 10, 1997, Pages 1275-1286

  Morral, Núria ^a   O'Neal, Wanda ^a   Zhou, Heshan ^a   Langston, Claire ^a   Beaudet, Arthur ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBODY; BETA GALACTOSIDASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE DELETION; GENE DOSAGE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; INFLAMMATION; LIVER; MOUSE; NONHUMAN; REPORTER GENE; TRANSGENIC MOUSE;

ADENOVIRIDAE; ANIMALIA; ESCHERICHIA COLI; MUS MUSCULUS;

EID: 0030824640     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.10-1275     Document Type: Article

References (47)

1. ABINA, M.A., LEE, M.G., DESCAMPS, V., CORDIER, L., LOPEZ, M., PERRICAUDET, M., and HADDADA, H. (1996). LacZ gene transfer into tumor cells abrogates tumorigenicity and protects mice against the development of further tumors. Gene Ther. 3, 212-216.
2. AKLI, S., CAILLAUD, C., VIGNE, E., STRATFORD-PERRICAUDET, L.D., POENARU, L., PERRICAUDET, M., KAHN, A., and PESCHANSKI, M.R. (1993). Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genet. 3, 224-228.
3. ARMENTANO, D., SOOKDEO, C.C., HEHIR, K.M., GREGORY, R.J., ST. GEORGE, J.A., PRINCE, G.A., WADSWORTH, S.C., and SMITH, A.E. (1995). Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6, 1343-1353.
4. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
5. BULLARD, D.C., KUNKEL, E.J., KUBO, H., HICKS, M.J., LORENZO, I., DOYLE, N.A., DOERSCHUK, C.M., LEY, K., and BEAUDET, A.L. (1996). Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice. J. Exp. Med. 183, 2329-2336.
6. CHEN, H.-H., MACK, L.M., KELLY, R., ONTELL, M., KOCHANEK, S., and CLEMENS, I.R. (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. USA 94, 1645-1650.
7. CONNELLY, S., GARDNER, J.M., LYONS, R.M., McCLELLAND, A., and KALEKO, M. (1996). Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87, 4671-4677.
8. DAI, Y., SCHWARZ, E.M., GU, D., ZHANG, W., and SARVETNICK, N. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92, 1401-1405.
9. DISEPIO, D., JONES, A., LONGLEY, M.A., BUNDMAN, D., ROTHNAGEL, J.A., and ROOP, D.R. (1995). The proximal promoter of the mouse loricrin gene contains a functional Ap-1 element and directs keratinocyte-specific but not differentiation-specific expression. J. Biol. Chem. 270, 10792-10799.
10. ENGELHARDT, J.F., SIMON, R.H., YANG, Y., ZEPEDA, M., WEBER-PENDLETON, S., DORANZ, B., GROSSMAN, M., and WILSON, J.M. (1993). Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Biological efficacy study. Hum. Gene Ther. 4, 759-769.
11. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994a). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91, 6196-6200.
12. ENGELHARDT, J.F., LITZKY, L., and WILSON, J.M. (1994b). Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5, 1217-1229.
13. - recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and dogs. Gene Ther. 3, 217-222.
14. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S., and WILSON, J.M. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
15. FRENCH, B.A., MAZUR, W., ALI, N.M., GESKE, R.S., FINNIGAN, J.P., RODGERS, G.P., ROBERTS, R., and RAIZNER, A.E. (1994). Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 90, 2402-2413.
16. GOLDMAN, M.J., LITZKY, L.A., ENGELHARDT, J.F., and WILSON, J.M. (1995). Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study. Hum. Gene Ther. 6, 839-851.
17. HARDY, S., KITAMURA, M., HARRIS-STANSIL, T., DAI, Y., and PHIPPS, M.L. (1997). Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71, 1842-1849.
18. HARMS, J.S., and SPLITTER, G.A. (1995). Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC 1 promoter. Hum. Gene Ther. 6, 1291-1297.
19. JAFFE, H.A., DANEL, C., LONGENECKER, G., METZGER, M., SETOGUCHI, Y., ROSENFELD, M.A., GANT, T.W., THORGEIRSSON, S.S., STRATFORD-PERRICAUDET, L.D., PERRICAUDET, M., PAVIRANI, A., LECOCQ, J.-P., and CRYSTAL, R.G. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet. 1, 372-378.
20. KAY, M., LI, Q.T., LIU, T.J., LELAND, F., TOMAN, C., FINEGOLD, M., and WOO, S.L.C. (1992). Hepatic gene therapy: Persistent expression of human alpha-1-antitrypsin in mice after direct gene delivery in vivo. Hum. Gene Ther. 3, 641-647.
21. KNODELL, R.G., ISHAK, K.G., BLACK, W.C., CHEN, T.S., CRAIG, R., KAPLOWITZ, N., KIERNAN, T.W., and WOLLMAN, J. (1981). Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431-435.
22. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.-H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA 93, 5731-5736.
23. KOZARSKY, K.F., JOOSS, K., DONAHEE, M., STRAUSS, J.F., and WILSON, J.M. (1996). Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nature Genet. 13, 54-62.
24. KROUGLIAK, V., and GRAHAM, F.L. (1995). Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum. Gene Ther. 6, 1575-1586.
25. LIEBER, A., HE, C., KIRILLOVA, I., and KAY, M.A. (1996). Recombinant adenoviruses with large deletions generated by cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70, 8944-8960.
26. MACGREGOR, G.R., MOGG, A.E., BURKE, J.F., and CASKEY, C.T. (1987). Histochemical staining of clonal mammalian cell lines expressing E. coli β-galactosidase indicate heterogeneous expression of the bacterial gene. Somatic Cell Mol. Genet. 13, 253-365.
27. MOULLIER, P., FRIEDLANDER, G., CALISE, D., RONCO, P., PERRICAUDET, M., and FERRY, N. (1994). Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int. 45, 1220-1225.
28. NIWA, H., YAMAMURA, K., and MIYAZAKI, J. (1991). Efficient selectin for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-200.
29. OHNO, T., GORDON, D., SAN, H., POMPILI, V.J., IMPERIALE, M.J., NABEL, G.J., and NABEL, E.G. (1994). Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265, 781-784.
30. PARKS, R.J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, M.A., and GRAHAM, F.L. (1996). A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93, 13565-13570.
31. QUANTIN, B., PERRICAUDET, L.D., TAJBAKHSH, S., and MANDEL, J.L. (1992). Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. USA 89, 2581-2584.
32. ROSENFELD, M.A., SIEGFRIED, W., YOSHIMURA, K., YONEYAMA, K., FUKAYAMA, M., STIER, L.E., PAAKKO, P.K., GILARDI, P., STRATFORD-PERRICAUDET, L.D., PERRICAUDET, M., JALLAT, S., PAVIRANI, A., LECOCQ, J., and CRYSTAL, R.G. (1991). Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo. Science 252, 431-434.
33. 1-antitrypsin to the systemic circulation. Am. J. Respir. Cell Mol. Biol. 10, 369-377.
34. STRATFORD-PERRICAUDET, L.D., LEVRERO, M., CHASSE, J., PERRICAUDET, M., and BRIAND, P. (1990). Evaluation of the trnasfer and expression in mice of an enzyme-encoding code using a human adenovirus vector. Hum. Gene Ther. 1, 241-256.
35. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
36. WADSWORTH, S., ZHOU, H., SMITH, A.E., and KAPLAN, J.M. (1997). Adenovirus vector transfected cells can escape adenovirus antigen-specific CTL killing in vivo. J. Virol. (in press).
37. WANG, Q., JIA, X., and FINER, M.H. (1995). A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 2, 775-783.
38. WILLS, K.N., MANEVAL, D.C., MENZEL, P., HARRIS, M.P., SUTJIPTO, S., VAILLANCOURT, M., HUANG, W., JOHNSON, D.E., ANDERSON, S.C., WEN, S.F., BOOKSTEIN, R., SHEPARD, H.M., and GREGORY, R.J. (1994). Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5, 1079-1088.
39. YANG, Y., NUNES, F.A., BERENCSI, K., FORTH, E.E., GÖNCZÖL, E., and WILSON, J.M. (1994a). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.
40. YANG, Y., NUNES, F.A., BERENCSI, K., GÖNCZÖPL, E., ENGELHARDT, J.F., and WILSON, J.M. (1994b). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7, 362-369.
41. YANG, Y., ERTL, H.C., and WILSON, J.M. (1994c). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1, 433-442.
42. YANG, Y., LI, Q., ERTL, H.C.J., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
43. YANG, Y., SU, Q., and WILSON, J.M. (1996a). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70, 7209-7212.
44. YANG, Y., JOOSS, K.U., SU, Q., ERTL, H.C.J., and WILSON, J.M. (1996b). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
45. YANG, Y., HAECKER, S.E., SU, Q., and WILSON, J.M. (1996c). Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet. 5, 1703-1712.
46. ZHOU, H., O'NEAL, W., MORRAL, N., and BEAUDET, A.L. (1996). Development of a complementing cell line and a system for construction of adenoviral vectors deleted for E1 and E2a. J. Virol. 70, 7030-7038.
47. ZSENGELLER, Z.K., WERT, S.E., HULL, W.M., HU, X., YEI, S., TRAPNELL, B.C., and WHITSETT, J.A. (1995). Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum. Gene Ther. 6, 457-467.